Fun for All Ages! Performance and Participatory Music & Dance, Juried
Craft Show, Children's Activities, Fabulous Food!
Admission, Performances, Dancing ar Free!
TAKOMA PARK, Md., Aug. 28 /PRNewswire-USNewswire/ -- Folks of all ages
who love traditional euphony and terpsichore from the U.S. and around the world
should enjoy the 31st Takoma Park Folk Festival, Sunday, Sept. 14 at Takoma
Park Middle School, 7611 Piney Branch Road, Takoma Park, MD. The free event
will escape from 11:00 a.m. to 6:30 p.m.
Music and dance is the heart of the festival, and the performances
range from traditional American folk styles to songwriters who comment on
current events. The Festival features "roots" music from Ruthie & the
Wranglers, Radio Caroline, The U-Liners, The New Misty Crystals, and
others. It includes the annual Showcase, with 11 newcomers who will each do
two songs before a panel of judges, world Health Organization will quality one success who volition get
a full 50-minute time slot in 2009. Other stages at the Festival volition
include a Bob Dylan Tribute and a two-hour segment of political songs.
"With septet stages of music and dance continuously, there's truly
something for everyone," said Kevin Adler, chairman. "We're really proud of
the diversity and quality of music that the Washington area has produced,
and we are grateful to the performers who come to our festival." Singing
along on the chorus and other audience participation is encouraged by many
performers, Adler renowned, adding that the festival offers "a uniquely
energizing experience."
Many artists have a global flair -- from the Samovar Russian Folk Music
Ensemble to Nrityanjali's dance styles from India to Capoeira Sul da Bahia,
a combining of dance and warlike arts from Brazil. Local Takoma Park
favorites Chopteeth volition close one of the stages with their high-energy
Afropop.
Adler added that none of the performers ar paid. "They are giving back
to the community, and their generosity makes the upshot possible," he said.
In addition to music and dance performances, the Festival includes:
-- Day-long participatory dance-beginners & kids welcome, most segments
include teaching
-- Juried craft fairish (45 artisans) with items designed and made by the
artisans
-- More than C community tables from local organizations
-- Games for young children
-- Twenty vendors oblation fabulous nutrient -- from healthy to decadent
This year too marks the debut of several young performers on the
Grassy Nook Stage. Most of the young performers hail from Takoma Park, and
some come from nearby Maryland and Virginia communities. Several of the
children have nationally-known performing artist parents, such as Steve Hickman and
Bill Wellington. The Twinbrook Tellers, storytellers ages 7-17 from the
Twinbrook Library in Rockville, also will be performing.
Grove Stage performers will inaugurate a brand-new platform. Work was
recently completed on the Folk Festival's Grove Stage -- the larger,
stronger surface will enable the Festival to welcome bigger bands to the
very popular locus. The Festival extends its appreciation to Concreto Plus
(construction), Landis Construction (design), the Arts & Humanities Council
of Montgomery County (funding), and the City of Takoma Park.
To see the complete political platform, or find directions for the shuttle or
walk, please chatter http://www.tpff.org.
Festival Goes Green: The festival is increasing its effort to "go
green" by using soy-based inks for printing t-shirts, recycling vendors'
leftover cooking oil into biodiesel, ending its purchase of bottled water,
and supporting recycling of bottles and cans.
Transportation Options: Free shuttle buses will run from the Takoma
Metro station and the Montgomery College parking garage. Walking directions
from each of those sites are on the Festival Website, and the walking
routes will as well be marked. Onsite parking is unavailable, and disabled
parking is extremely limited.
The Takoma Park Folk Festival is supported in part by funding from the
Arts and Humanities Council of Montgomery County and the Maryland State
Arts Council.
For more than information: hypertext transfer protocol://www.tpff.org; hypertext transfer protocol://www.myspace.com/tpfolkfest;
(301) 589-0202
More info
Sunday 31 August 2008
Thursday 21 August 2008
Rheb's Role In Cancer
�
Two independent papers in the August 15th number of G&D identify the Rheb GTPase as a novel transforming gene and a promising newfangled chemotherapeutic target.
The first paper, from Dr. Pier Paolo Pandolfi (BIDMC and Harvard Medical School) and colleagues, demonstrates that the Ras-like small GTPase, Rheb, is directly involved in prostate tumorigenesis.
Through the overexpression of Rheb specifically in prostate gland tissue of live mice, the researchers were able-bodied to establish that increased Rheb signal activity is sufficient to induce low-grade prostate neoplasias. Furthermore, in combination with decreased PTEN activity, Rheb overexpression keister stimulate belligerent prostate tumor formation.
"The identification of Rheb as a gene involved in the pathogenesis of cancer opens new avenues for the development of anti-cancer therapies, as Rheb is an inherently 'druggable' target. Indeed, we ar already testing such drugs alone, and in combination with other chemotherapeutics in faithful animate being models," explains Dr. Pandolfi.
In the attendant paper, Dr. Hans-Guido Wendel (Memorial Sloan Kettering Cancer Center) and colleagues stage evidence that Rheb can also function as an oncogene in lymphomagenesis.
Using an experimental beast model of human lymphoma, the researchers demonstrated that Rheb overexpression contributes to lymphoma formation. They as well pinpointed Rheb overexpression as a course occurring hereditary mutation in human patient-derived lymphoma tumor samples. In addition, Dr. Wendel and colleagues establish that the targeted inhibition of Rheb can efficaciously counteract tumor progression in lymphomas with this unique genetic signature.
Dr. Wendel emphasizes that "The key clinical implication is that Rheb levels in tumor tissue could designate patients that will benefit from relatively non-toxic therapies with targeted drugs like rapamyicn or inhibitors of the farnesyltransferase enzyme."
Source:
Heather Cosel-Pieper
Cold Spring Harbor Laboratory
More info
Two independent papers in the August 15th number of G&D identify the Rheb GTPase as a novel transforming gene and a promising newfangled chemotherapeutic target.
The first paper, from Dr. Pier Paolo Pandolfi (BIDMC and Harvard Medical School) and colleagues, demonstrates that the Ras-like small GTPase, Rheb, is directly involved in prostate tumorigenesis.
Through the overexpression of Rheb specifically in prostate gland tissue of live mice, the researchers were able-bodied to establish that increased Rheb signal activity is sufficient to induce low-grade prostate neoplasias. Furthermore, in combination with decreased PTEN activity, Rheb overexpression keister stimulate belligerent prostate tumor formation.
"The identification of Rheb as a gene involved in the pathogenesis of cancer opens new avenues for the development of anti-cancer therapies, as Rheb is an inherently 'druggable' target. Indeed, we ar already testing such drugs alone, and in combination with other chemotherapeutics in faithful animate being models," explains Dr. Pandolfi.
In the attendant paper, Dr. Hans-Guido Wendel (Memorial Sloan Kettering Cancer Center) and colleagues stage evidence that Rheb can also function as an oncogene in lymphomagenesis.
Using an experimental beast model of human lymphoma, the researchers demonstrated that Rheb overexpression contributes to lymphoma formation. They as well pinpointed Rheb overexpression as a course occurring hereditary mutation in human patient-derived lymphoma tumor samples. In addition, Dr. Wendel and colleagues establish that the targeted inhibition of Rheb can efficaciously counteract tumor progression in lymphomas with this unique genetic signature.
Dr. Wendel emphasizes that "The key clinical implication is that Rheb levels in tumor tissue could designate patients that will benefit from relatively non-toxic therapies with targeted drugs like rapamyicn or inhibitors of the farnesyltransferase enzyme."
Source:
Heather Cosel-Pieper
Cold Spring Harbor Laboratory
More info
Monday 11 August 2008
Multaq(R) (dronedarone) Granted FDA Priority Review For Patients With Atrial Fibrillation
�Sanofi-aventis
(EURONEXT: SAN and NYSE: SNY) announced that U.S. Food and Drug
Administration (FDA) has assigned priority recap status for its New Drug
Application (NDA) for Multaq(R) (dronedarone). The precedence review period
begins on July 31, 2008.
The priority review is given to applications in which a modern
indication or new drug product, if approved, has the potential drop to present a
safe and effective therapy where no satisfactory alternative exists
compared to currently available therapies or marketed products.
A enrollment dossier is also under regulatory review by the European
Medicines Agency (EMEA) for a Marketing Authorization Application.
"We are proud of that the FDA has designated Multaq(R) for precedency
review," aforesaid Marc Cluzel, sanofi-aventis Senior Vice President, R&D for
sanofi-aventis. "This follows the exciting results of the landmark ATHENA
study that showed Multaq(R) significantly reduced the risk of
cardiovascular hospitalizations or death from any grounds in patients with
Atrial Fibrillation."
Atrial fibrillation is a major cause of hospitalization and mortality
and affects virtually 2.5 million people in the United States, as well as 4.5
trillion people in the European Union and is emerging as a growing populace
health concern due to an ripening population. Patients suffering from atrial
fibrillation have twice the risk of death, an increased risk of stroke and
cardiovascular complications, including congestive heart bankruptcy.
Furthermore atrial fibrillation well impairs patients' lives,
primarily because of their inability to perform normal daily activities due to
complaints of palpitations, chest pain, dyspnoea, fatigue or
light-headedness.
About Multaq(R) (dronedarone)
Dronedarone (brand diagnose Multaq(R)) is an investigational new handling
for patients with atrial fibrillation, which has been discovered and
developed by sanofi-aventis for the bar and handling of patients
with atrial fibrillation or atrial flutter. Dronedarone is a multi-channel
blocker that affects calcium, potassium and sodium channels and has
anti-adrenergic properties. Dronedarone does not contain the iodine radical
and did non show any evidence of thyroid or pulmonary toxicity in clinical
trials.
About Sanofi Aventis
Sanofi-aventis, a preeminent global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Forward Looking Statements
This weigh release contains forward-looking statements as defined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements ar statements that are non historical facts.
These statements include product development, mathematical product potential projections
and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future events,
operations, products and services, and statements regarding future
performance. Forward-looking statements are generally identified by the
words "expects," "anticipates," "believes," "intends," "estimates," "plans"
and similar expressions. Although sanofi-aventis' management believes that
the expectations reflected in such forward-looking statements are
reasonable, investors ar cautioned that forward-looking selective information and
statements are subject to versatile risks and uncertainties, many of which
are difficult to promise and generally beyond the control of
sanofi-aventis, that could suit actual results and developments to disagree
materially from those explicit in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post selling,
decisions by regulatory regime, such as the FDA or the EMEA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labeling and other matters that could affect the availability or
commercial voltage of such products candidates, the absence of vouch
that the products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutic alternatives as
well as those discussed or identified in the public filings with the SEC
and the AMF made by sanofi-aventis, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on Form 20-F for the year ended December 31,
2007. Other than as required by applicable constabulary, sanofi-aventis does not
undertake any duty to update or revise any advanced
information or statements.
Sanofi Aventis
http://www.sanofi-aventis.com
More info
(EURONEXT: SAN and NYSE: SNY) announced that U.S. Food and Drug
Administration (FDA) has assigned priority recap status for its New Drug
Application (NDA) for Multaq(R) (dronedarone). The precedence review period
begins on July 31, 2008.
The priority review is given to applications in which a modern
indication or new drug product, if approved, has the potential drop to present a
safe and effective therapy where no satisfactory alternative exists
compared to currently available therapies or marketed products.
A enrollment dossier is also under regulatory review by the European
Medicines Agency (EMEA) for a Marketing Authorization Application.
"We are proud of that the FDA has designated Multaq(R) for precedency
review," aforesaid Marc Cluzel, sanofi-aventis Senior Vice President, R&D for
sanofi-aventis. "This follows the exciting results of the landmark ATHENA
study that showed Multaq(R) significantly reduced the risk of
cardiovascular hospitalizations or death from any grounds in patients with
Atrial Fibrillation."
Atrial fibrillation is a major cause of hospitalization and mortality
and affects virtually 2.5 million people in the United States, as well as 4.5
trillion people in the European Union and is emerging as a growing populace
health concern due to an ripening population. Patients suffering from atrial
fibrillation have twice the risk of death, an increased risk of stroke and
cardiovascular complications, including congestive heart bankruptcy.
Furthermore atrial fibrillation well impairs patients' lives,
primarily because of their inability to perform normal daily activities due to
complaints of palpitations, chest pain, dyspnoea, fatigue or
light-headedness.
About Multaq(R) (dronedarone)
Dronedarone (brand diagnose Multaq(R)) is an investigational new handling
for patients with atrial fibrillation, which has been discovered and
developed by sanofi-aventis for the bar and handling of patients
with atrial fibrillation or atrial flutter. Dronedarone is a multi-channel
blocker that affects calcium, potassium and sodium channels and has
anti-adrenergic properties. Dronedarone does not contain the iodine radical
and did non show any evidence of thyroid or pulmonary toxicity in clinical
trials.
About Sanofi Aventis
Sanofi-aventis, a preeminent global pharmaceutical company, discovers,
develops and distributes therapeutic solutions to improve the lives of
everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York
(NYSE: SNY).
Forward Looking Statements
This weigh release contains forward-looking statements as defined in
the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements ar statements that are non historical facts.
These statements include product development, mathematical product potential projections
and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future events,
operations, products and services, and statements regarding future
performance. Forward-looking statements are generally identified by the
words "expects," "anticipates," "believes," "intends," "estimates," "plans"
and similar expressions. Although sanofi-aventis' management believes that
the expectations reflected in such forward-looking statements are
reasonable, investors ar cautioned that forward-looking selective information and
statements are subject to versatile risks and uncertainties, many of which
are difficult to promise and generally beyond the control of
sanofi-aventis, that could suit actual results and developments to disagree
materially from those explicit in, or implied or projected by, the
forward-looking information and statements. These risks and uncertainties
include among other things, the uncertainties inherent in research and
development, future clinical data and analysis, including post selling,
decisions by regulatory regime, such as the FDA or the EMEA, regarding
whether and when to approve any drug, device or biological application that
may be filed for any such product candidates as well as their decisions
regarding labeling and other matters that could affect the availability or
commercial voltage of such products candidates, the absence of vouch
that the products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutic alternatives as
well as those discussed or identified in the public filings with the SEC
and the AMF made by sanofi-aventis, including those listed under "Risk
Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in
sanofi-aventis' annual report on Form 20-F for the year ended December 31,
2007. Other than as required by applicable constabulary, sanofi-aventis does not
undertake any duty to update or revise any advanced
information or statements.
Sanofi Aventis
http://www.sanofi-aventis.com
More info
Subscribe to:
Posts (Atom)